European Society for Medical Oncology, 2024 - Gastrointestinal oncology
Adoption of Medical Remote Monitoring in Gastrointestinal Oncology: A Real-World Study of 2,416 Patients Across 59 Centers in France and Belgium.
Dec 4, 2025
2 minutes
Authors
Jérôme Desramé 1, Sahir Javed 2, Vincent Heinschild 3, Christophe Desauw 4, Alina Fuerea 5, Thomas Papazyan 6, Charles Ferté 6, Marine Valéry 5, Pascal Artru 1, Michel Ducreux 5.
Affiliation
1. Hôpital Privé Jean Mermoz, Lyon, France ; 2. Centre Hospitalier de Valenciennes, Valenciennes, France ; 3. Nouvelle Clinique Bordeaux Tondu, Bordeaux, France ; 4. Centre Hospitalier Universitaire de Lille, Lille, France ; 5. Gustave Roussy, Villejuif, France ; Resilience, France.
Introduction
Medical remote monitoring based on ePROs (electronic Patient-Reported Outcomes) has demonstrated clinical and organizational benefits through Phase III randomized controlled clinical trials[1-4]. These benefits include:
- Symptom control,
- Quality of life,
- Increased relative dose intensity,
- Reduction in the number of hospitalizations,
- Prolongation of overall survival.
Consequently, in 2022, ESMO published its recommendations regarding medical remote monitoring for routine clinical practice during anti-cancer treatments[5].
However, patient adherence and the benefits of remote monitoring in gastrointestinal oncology remain unknown. This study presents and analyzes the implementation and deployment of a medical remote monitoring solution in gastrointestinal oncology.
Poster presented at the 2024 ESMO (European Society of Medical Oncology) Congress.
Sources
1. Mir O, Ferrua M, Fourcade A, et al. Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial. Nat Med.2022;28(6):1224-1231.
2. Basch E, Schrag D, Henson S, et al. Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer: A Randomized Clinical Trial. JAMA. 2022;327(24):2413-2422.
3. Basch E, Deal AM, Kris MG, et al. Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial. J Clin Oncol. 2019 Feb20;37(6):528.
4. Basch E, Deal AM, Dueck AC, et al. Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. JAMA.2017;318(2):197-198.
5. Di Maio M, Basch E, Denis F, et al. The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline. Ann Oncol. 2022;33(9):878-892. doi:10.1016/j.annonc.2022.04.007.
